Literature DB >> 24039155

Adoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation.

Matteo Di Nardo1, Giuseppina Li Pira, Antonio Amodeo, Corrado Cecchetti, Ezio Giorda, Stefano Ceccarelli, Letizia P Brescia, Nicola Pirozzi, Sergio Rutella, Franco Locatelli, Alice Bertaina.   

Abstract

We report on the successful infusion of human adenovirus (HAdV)-specific T cells in a child with congenital amegakaryocytic thrombocytopenia, given T-cell-depleted hematopoietic stem cell transplantation (HSCT) from the HLA-haploidentical mother during extracorporeal membrane oxygenation (ECMO) for severe HAdV-related respiratory failure. Donor-derived, interferon (IFN)-γ-secreting HAdV-specific T cells were enriched using the cytokine capture assay, after in vitro stimulation with overlapping peptides from the immunodominant HAdV5 hexon protein. Two weeks after T-cell transfer, viral load decreased and ECMO was discontinued. T-cell responses to HAdV antigens were documented after four weeks and were associated with viral clearance, immune reconstitution and clinical amelioration.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ECMO; T lymphocyte; adenovirus; immune recovery; immunotherapy; stem cell transplantation

Mesh:

Substances:

Year:  2013        PMID: 24039155     DOI: 10.1002/pbc.24753

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Extracorporeal membrane oxygenation in pediatric recipients of hematopoietic stem cell transplantation: an updated analysis of the Extracorporeal Life Support Organization experience.

Authors:  Matteo Di Nardo; Franco Locatelli; Kenneth Palmer; Antonio Amodeo; Roberto Lorusso; Mirko Belliato; Corrado Cecchetti; Daniela Perrotta; Sergio Picardo; Alice Bertaina; Sergio Rutella; Peter Rycus; Vincenzo Di Ciommo; Bernhard Holzgraefe
Journal:  Intensive Care Med       Date:  2014-02-21       Impact factor: 17.440

Review 2.  Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.

Authors:  Matteo Di Nardo; Ali H Ahmad; Pietro Merli; Matthew S Zinter; Leslie E Lehman; Courtney M Rowan; Marie E Steiner; Sangeeta Hingorani; Joseph R Angelo; Hisham Abdel-Azim; Sajad J Khazal; Basirat Shoberu; Jennifer McArthur; Rajinder Bajwa; Saad Ghafoor; Samir H Shah; Hitesh Sandhu; Karen Moody; Brandon D Brown; Maria E Mireles; Diana Steppan; Taylor Olson; Lakshmi Raman; Brian Bridges; Christine N Duncan; Sung Won Choi; Rita Swinford; Matt Paden; James D Fortenberry; Giles Peek; Pierre Tissieres; Daniele De Luca; Franco Locatelli; Selim Corbacioglu; Martin Kneyber; Alessio Franceschini; Simon Nadel; Matthias Kumpf; Alessandra Loreti; Roelie Wösten-Van Asperen; Orsola Gawronski; Joe Brierley; Graeme MacLaren; Kris M Mahadeo
Journal:  Lancet Child Adolesc Health       Date:  2021-12-09

Review 3.  Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.

Authors:  C Qian; Y Wang; L Reppel; M D'aveni; A Campidelli; V Decot; D Bensoussan
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

4.  Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network's Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup.

Authors:  Matt S Zinter; Jennifer McArthur; Christine Duncan; Roberta Adams; Erin Kreml; Heidi Dalton; Hisham Abdel-Azim; Courtney M Rowan; Shira J Gertz; Kris M Mahadeo; Adrienne G Randolph; Prakadeshwari Rajapreyar; Marie E Steiner; Leslie Lehmann
Journal:  Pediatr Crit Care Med       Date:  2022-03-01       Impact factor: 3.624

5.  Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture.

Authors:  Valérie Janelle; Cédric Carli; Julie Taillefer; Julie Orio; Jean-Sébastien Delisle
Journal:  J Transl Med       Date:  2015-04-19       Impact factor: 5.531

6.  Successful engraftment after hematopoietic stem cell transplantation with infusion of donor stem cells through the extracorporeal membrane oxygenation circuit.

Authors:  Pilar Anton-Martin; Cindy Darnell-Bowens; Victor M Aquino; Teresa Jones; Lakshmi Raman
Journal:  Indian J Crit Care Med       Date:  2016-10

7.  Extracorporeal life support survival in a pediatric hematopoietic cellular transplant recipient with presumed GvHD-related fulminant myocarditis.

Authors:  M S Zinter; B D Barrows; P C Ursell; K Kowalek; K Kalantar; N Cambronero; J L DeRisi; P Oishi; C C Dvorak
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

8.  Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Authors:  Chongsheng Qian; Arnaud Campidelli; Yingying Wang; Huili Cai; Véronique Venard; Hélène Jeulin; Jean Hugues Dalle; Cécile Pochon; Maud D'aveni; Benedicte Bruno; Catherine Paillard; Stéphane Vigouroux; Charlotte Jubert; Patrice Ceballos; Aude Marie-Cardine; Claire Galambrun; Clément Cholle; Isabelle Clerc Urmes; Nadine Petitpain; Marcelo De Carvalho Bittencourt; Véronique Decot; Loïc Reppel; Alexandra Salmon; Laurence Clement; Danièle Bensoussan
Journal:  J Hematol Oncol       Date:  2017-05-08       Impact factor: 17.388

Review 9.  T-Cell Manipulation Strategies to Prevent Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation.

Authors:  Jayakumar Vadakekolathu; Sergio Rutella
Journal:  Biomedicines       Date:  2017-06-21

Review 10.  Virus-Specific T Cells for the Immunocompromised Patient.

Authors:  Amy Houghtelin; Catherine M Bollard
Journal:  Front Immunol       Date:  2017-10-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.